Labiotech.eu’s Post

Big confluence of factors driving an ever bigger market opportunity. The War on Cancer will never end, and never not keep attracting outsized investment up and down the stack. "The market is primarily driven by factors such as an increase in technological advancements, a rise in cancer incidences, and improvements in personalized medicine and cell and gene therapies, which are starting new approaches for developing new treatments for cancer-like diseases. Moreover, an increase in funding from pharmaceutical and biotech companies, non-profit organizations, and CROs for oncology clinical trials is further supporting market growth and the development of advanced products to gain substantial market share." #5ForcesofHCT #Pharma #Cancer #ClinicalTrials #Biotech #Biopharma https://lnkd.in/gTEyCcUz

🔎𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 Evox Therapeutics Ltd Targets protein misfolding in diseases like Alzheimer's and cancer. Sana Biotechnology, Inc. Uses gene editing for curative cell therapies in blood diseases. Ikena Oncology Targets unique metabolic pathways in hard-to-treat cancers. Pionyr Immunotherapeutics Develops next-gen immunotherapies to supercharge a patient's immune system against cancer. BlueWillow Biologics, Inc. Pioneering a new approach to target RNA for treating neurodegenerative diseases like ALS. Absci Uses AI to speed up drug discovery, leading to faster development of new treatments. Let me know in the comments any other biotech's to watch out for 👇🏼 #biotech #research #drugdevelopment #drugdiscovery

Epoch 17: Sweat Equity - Your Weekly Biotech News Fix Designed to be consumed as a quick scroll + links to the source articles 👉 Biopharma hirings & VISAs 👉 $MRNA working with OpenAI ChatBots 👉 $BIIB PPD drug estimated $500M PYS 👉 David Baker desings peptide-like drugs 👉 $BIIB update on M&A strategy 👉 $DAWN accelerated approval for pediatric cancer 👉 Japan biotech pharma collaboration 👉 Xaira launches with $1B financing 👉 MASSIVE BMS RIF 👉 $REGN gene editing deal with Mammoth 👉Endeavor $132M financing for fibrosis 👉Neurocrine with major breakthrough in MDD And more! https://lnkd.in/dEkBy2bY

Ginkgo, in search of more cell therapy tools, buys another startup https://lnkd.in/g_XZ4zyB Ginkgo Bioworks is expanding its ability to help other companies make cell and gene therapies, this time by acquiring a startup with tools to improve cell-based treatments. Ginkgo on Tuesday announced it has bought Modulus Therapeutics, a Seattle-based biotechnology startup. Ginkgo didn’t disclose the financial terms, but noted in a statement that the technology Modulus owns has the potential to boost the safety and efficacy of cell therapies. Modulus is one of many startups exploring cell therapy for autoimmune conditions , rather than the blood cancers that approved cellular medicines are now used to treat. While Modulus formed in 2020 with a focus on oncology and raised close to $4 million in seed funding a year later, its website now bills the company as an autoimmune cell therapy maker. It hasn’t announced any further funding rounds. The company claims it has tools to discover new “CARs,”… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Epoch 8: Sweat Equity - Your Weekly Biotech News Fix To be consumed as a quick scroll. Detailed linked provided for additional reading. 👉 USA/China Biosecure Act 👉 Fetal Gene Editing 👉 Failed Oncology Deals Post-Mortem 👉 Drug Makers Unite Against IRA 👉 1st Tumor-Infiltrating Lymphocyte product 👉 New $260M VC fund to use AI to id winners 👉 Top 10 biotech deals >$1B since July 2023 👉 $100M for Womens's Health 👉 FTC meddling in AbbVie/Cerevel deal 👉 A Buyers market for biotech in 2024 👉 CAR-T for Auto-Immune Disease 👉 CEO Swap AbbVie 👉 Fractional C-Suites in Biotech 👉 and more! https://lnkd.in/dEkBy2bY

The Overlooked Simplicity in Biomarker Discovery I'm all for large omics studies and the utility they have in understanding the mechanism of action, especially in the preclinical setting. But, in the early stages of clinical trials, the heterogeneity (often multiple indications and disease stages) and high costs associated with biomarker mining challenge its budget effectiveness and statistical value. Many of the features in a comprehensive gene assay are not of appropriate prevalence in the population or have enough dynamic range to make it a robust biomarker. Historical successes, such as the identification of PSA for prostate cancer, exemplify the potential of targeted, hypothesis-driven research over complex methodologies. Embracing simplicity could lead to more scientifically and economically efficient discoveries, aligning closely with clinical utility and real-world applicability. #biomarkerdiscovery #biomarkers #clinicaltrials ---- Hi, I'm Josie, a strategic biomarker consultant. I provide advice to therapeutics companies on preclinical and clinical biomarker strategy. Follow me to hear more of this or schedule a call with me for a free intro chat.

This week in the world of #biotech #fundraising : 🇺🇸 Korro Bio, Inc. | $117 million PIPE | RNA editing | clinical in alpha-1 antitrypsin deficiency (AATD) 🇺🇸 LEXEO Therapeutics | $100 million IPO | gene therapies | phase 1/2 in cardiac Friedreich’s ataxia and Alzheimer’s disease 🇺🇸 Gate Bioscience | $60 million series A | molecular gates | drug discovery stage 🇺🇸 Imagine Pharma | $32.5 million series A | therapeutic and regenerative medicine | phase 1 for anemia in patients with renal failure, undergoing chemotherapy and other causes 🇨🇭 Memo Therapeutics AG | CHF 25 million ($27.76 million) series C | antibody-based therapies | phase 2/3 in BK virus infection in kidney transplant recipients 🇺🇸 ProJenX | $15 million series A | brain-penetrant kinase inhibitors | clinical in amyotrophic lateral sclerosis (ALS) 🇧🇪 Amyl Therapeutics | €5 million ($5.35 million) series A extension | amyloid-targeting therapies | preclinical in amyloid light chain (AL) amyloidosis 💡My take on it: We haven't seen an IPO in a while, but since Lexeo's didn't go particularly well (stock fell 15% in trading debut), we may see even more companies shying away from the public market.

Biotech's Role in Pharma M&A Big pharma is increasingly acquiring biotech firms to tap into their cutting-edge therapies, especially in oncology and gene therapy. In 2023 alone, M&A deal values exceeded $200 billion. Biotechs, leading in targeted cancer treatments and gene therapies, are revolutionizing patient care. These acquisitions enhance big pharma’s R&D pipelines, with over 60% of new drugs now originating from biotech. Strategic synergies between pharma giants and biotech startups create powerful collaborations, combining resources and expertise to bring advanced treatments to market more efficiently. #Pharma #MergersAndAcquisitions #Biotech #Innovation #Healthcare

In last week's newsletter "Where Tech Meets Bio": Weekly tech+bio highlights; Seed Health Invests in AI-Driven Biology Platform to Enhance Microbiome Science; Novel Gen AI Platform for Preclinical Research; This Company's ML Model Predicts KRAS Inhibitor's Clinical Benefit in Patients with >80% Accuracy; Model Medicines Advances AI Drug Discovery in Antiviral and Oncology Fields; A Novel Quantum-assisted Approach to Designing Drugs From Fragments; Cancer Vaccines: insights from #AACR24 Mapping AI-driven drug candidates and targets (infographic) Read the newsletter via the link in the comments and subscribe to not miss future weekly insights about emerging technologies in the life sciences! #biopharmatrend #WhereTechMeetsBio #techbio

🎬 Introducing a brand new video series called "Tom's Top 3"! Join me as I delve into the latest buzz in healthcare innovation, highlighting three captivating stories shaping the industry. In our inaugural episode, we'll be exploring: 1️⃣ Groundbreaking gene therapies revolutionizing rare disease treatments. 2️⃣ Big moves in biologics manufacturing with significant acquisitions. 3️⃣ Impactful collaborations driving progress in pediatric cancer care. Insights into further stories to highlight over the coming weeks will be greatly appreciated! Stay tuned and let's embark on this journey together. #TomsTop3 #HealthcareUpdates #Innovation #LinkedInCommunity 🚀🩺 Links to the full articles can be found in the comments!